50
Participants
Start Date
August 31, 2025
Primary Completion Date
August 31, 2026
Study Completion Date
August 31, 2026
Romiplostim N01
The subjects will receive ropivacaine N01 treatment, with an initial dose of (2-3) µg/kg. When the dose is less than 250 µg, 250 µg (1 vial) can be administered (subcutaneously), once a week. The dose will be increased by (1) µg/kg each week, up to a maximum of 10 µg/kg, until the platelet count reaches ≥ 50 × 10\^9/L. If the platelet count returns to normal, the dose can be reduced according to the platelet level as appropriate.
RECRUITING
Chinese Academy of Medical Science and Blood Disease Hospital, Tianjin
Tianjin Medical University Cancer Institute and Hospital
OTHER
Tianjin Medical University Second Hospital
OTHER
Tianjin Third Central Hospital
OTHER
Tianjin People's Hospital
OTHER
Henan Cancer Hospital
OTHER_GOV
The Second Affiliated Hospital of Kunming Medical University
OTHER
Institute of Hematology & Blood Diseases Hospital, China
OTHER